Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
Investigating novel peripheral blood biomarkers for disease activity and treatment response in multiple sclerosis
EF 2020-21
Résumé
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) and represents the most common neurological disorder among young adults. There is no blood test to follow disease activity. A biomarker is a biological indicator of disease activity. Because of the variable course of the disease and inconsistent response to treatments, the lack of readily measurable biomarkers is an obstacle to the early and correct treatment of people with MS. To address this clinical need, I used gene expression analysis to uncover differences between immune cells from MS patients and healthy controls. I hypothesize that the levels of proteins resulting from the expression of differently expressed genes can be indicative of relapses and/or response to treatment. To conduct my biomarker study, I will study seven potential biomarkers simultaneously on individual cells using a technique called flow cytometry. I will analyze immune cells from a bank of MS patient samples in the Prat lab. I will select samples from MS patients at different stages of the disease, with different disease activity, under different treatments, and at different timepoints in their disease course. Next, I will compare the levels of the potential biomarkers on different immune cell types in the conditions listed above. Finally, I will correlate the flow cytometry data with clinical and magnetic resonance imaging (MRI) data. This may lead to the first MS blood biomarker for potential clinical use. Such a biomarker could allow physicians to predict patient disease course, but also to effectively determine treatment response and thus promote rapid adjustments to treatment regimes. This would undoubtedly promote better clinical care of people with MS and drastically improve their quality of life.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449625
Name
Thai Karine
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating novel peripheral blood biomarkers for disease activity and treatment response in multiple sclerosis
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Flow Cytometry; Multiple Sclerosis; Neurodegenerative Disease; Neuroimmunology; Scrna-Seq
Abstract
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) and represents the most common neurological disorder among young adults. There is no blood test to follow disease activity. A biomarker is a biological indicator of disease activity. Because of the variable course of the disease and inconsistent response to treatments, the lack of readily measurable biomarkers is an obstacle to the early and correct treatment of people with MS. To address this clinical need, I used gene expression analysis to uncover differences between immune cells from MS patients and healthy controls. I hypothesize that the levels of proteins resulting from the expression of differently expressed genes can be indicative of relapses and/or response to treatment. To conduct my biomarker study, I will study seven potential biomarkers simultaneously on individual cells using a technique called flow cytometry. I will analyze immune cells from a bank of MS patient samples in the Prat lab. I will select samples from MS patients at different stages of the disease, with different disease activity, under different treatments, and at different timepoints in their disease course. Next, I will compare the levels of the potential biomarkers on different immune cell types in the conditions listed above. Finally, I will correlate the flow cytometry data with clinical and magnetic resonance imaging (MRI) data. This may lead to the first MS blood biomarker for potential clinical use. Such a biomarker could allow physicians to predict patient disease course, but also to effectively determine treatment response and thus promote rapid adjustments to treatment regimes. This would undoubtedly promote better clinical care of people with MS and drastically improve their quality of life.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thai, Karine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~